Fahimtar yawan coagulation na jini: matsakaicin adadin da kuma mahimmancin lafiya

A fannin lafiyar lafiya, aikin coagulation na jini babban haɗi ne wajen kiyaye yanayin jikin ɗan adam na yau da kullun. Yawan coagulation na jini, wanda yawanci ake aunawa ta hanyar alamun coagulation, yana taka muhimmiyar rawa wajen tantance yanayin lafiyar jikin ɗan adam. To, menene adadin coagulation na jini na yau da kullun? Wannan batu yana da alaƙa da ganewar asali da kuma maganin marasa lafiya da yawa, kuma ya jawo hankali sosai daga ƙwararrun likitoci da jama'a.

Gabaɗaya dai, alamun gwajin aikin coagulation da aka saba amfani da su a aikin asibiti sun haɗa da lokacin prothrombin (PT), lokacin thromboplastin mai aiki (APTT), lokacin thrombin (TT) da fibrinogen (FIB).
Matsakaicin jeri na waɗannan alamun sune:
Lokacin Prothrombin (PT) yawanci yana tsakanin daƙiƙa 10 zuwa 14, kuma yana da mahimmanci a asibiti idan ya wuce ikon sarrafawa na yau da kullun da fiye da daƙiƙa 3;
Matsakaicin lokacin da aka kunna na'urar thromboplastin (APTT) shine daƙiƙa 25 zuwa 37, kuma idan ya wuce ikon sarrafawa na yau da kullun da fiye da daƙiƙa 10, ya kamata a ɗauke shi da mahimmanci;
Lokacin da aka saba amfani da thrombin (TT) shine daƙiƙa 12 zuwa 16, kuma wuce lokacin da aka saba amfani da shi fiye da daƙiƙa 3 yana nuna cewa akwai yiwuwar samun matsaloli;
Matsakaicin abun ciki na fibrinogen (FIB) yana tsakanin 2 zuwa 4 g/L.

Duk da haka, ya kamata a lura cewa saboda bambance-bambance a cikin hanyoyin dubawa, abubuwan da ake amfani da su da kayan aiki da asibitoci daban-daban ke amfani da su, ƙimar coagulation na yau da kullun na iya ɗan bambanta. Saboda haka, takamaiman kewayon ma'auni na yau da kullun ya kamata ya dogara ne akan nau'in rahoton asibiti inda aka yi wa majiyyaci magani.

Yawan coagulation mara kyau sau da yawa yana da alaƙa da cututtuka iri-iri. Idan yawan coagulation ya yi yawa, yana iya zama saboda cututtuka kamar thrombocytosis, polycythemia vera, da coagulation mai yaɗuwa a cikin jijiyoyin jini, wanda ke ƙara coagulation na jini don haka yana ƙara haɗarin thrombosis. Bugu da ƙari, wasu magunguna kamar anticoagulants (heparin, warfarin), magungunan antiplatelet (aspirin, clopidogrel), magungunan chemotherapy, da jiyya kamar hemodialysis da oxygenation na membrane extracorporeal (ECMO) suma na iya shafar aikin coagulation, wanda ke haifar da coagulation mai yawa. Akasin haka, aikin coagulation mara kyau kuma yana iya faruwa ne sakamakon ƙarancin coagulation na gado, ƙarancin bitamin K, thrombocytopenia, yawan amfani da magungunan anticoagulants, da cututtukan shan coagulation. Waɗannan yanayi na iya haifar da matsalolin coagulation na jini kuma suna iya zubar jini.

Ga jama'a, yana da matuƙar muhimmanci a fahimci yawan coagulation na yau da kullun da kuma ilimin da ya dace game da aikin coagulation na rashin daidaituwa. Idan aka sami adadin coagulation na rashin daidaituwa yayin gwajin jiki ko magani, ya kamata a tuntuɓi likita akan lokaci don fayyace dalilin da kuma ɗaukar matakan magani masu dacewa. A lokaci guda, gwaje-gwajen jiki na yau da kullun da kuma kiyaye rayuwa mai kyau suma suna da kyau don kiyaye aikin coagulation na yau da kullun.

Kamfanin Beijing Succeeder Technology Inc. (lambar hannun jari: 688338) ya daɗe yana aiki a fannin gano cutar coagulation tun lokacin da aka kafa shi a shekarar 2003, kuma ya kuduri aniyar zama jagora a wannan fanni. Kamfanin da ke hedikwata a Beijing, yana da ƙungiyar bincike da ci gaba, samarwa da tallace-tallace masu ƙarfi, suna mai da hankali kan ƙirƙira da amfani da fasahar gano cutar thrombosis da hemostasis.

Tare da ƙarfin fasaha mai ban mamaki, Succeeder ya lashe haƙƙin mallaka guda 45 da aka amince da su, waɗanda suka haɗa da haƙƙin mallaka guda 14 na ƙirƙira, haƙƙin mallaka guda 16 na samfuran amfani da haƙƙin mallaka guda 15. Kamfanin yana kuma da takaddun shaidar rajistar samfuran na'urorin likitanci guda 32 na Aji II, takaddun shaida na shigarwa na Aji I guda 3, da kuma takardar shaidar CE ta EU ga samfura 14, kuma ya wuce takardar shaidar tsarin kula da inganci na ISO 13485 don tabbatar da inganci da kwanciyar hankali na ingancin samfura.

Succeeder ba wai kawai wani muhimmin kamfani ne na Shirin Ci Gaban Masana'antar Magungunan Halittu na Beijing (G20) ba, har ma ya samu nasarar shiga Hukumar Kirkire-kirkire ta Kimiyya da Fasaha a shekarar 2020, wanda hakan ya kai ga ci gaban kamfanin. A halin yanzu, kamfanin ya gina hanyar sadarwa ta tallace-tallace a duk fadin kasar da ta shafi daruruwan wakilai da ofisoshi. Ana sayar da kayayyakinsa sosai a mafi yawan sassan kasar. Haka kuma yana fadada kasuwannin kasashen waje tare da ci gaba da inganta gasa a duniya.